Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people.
Pfizer announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for Covid-19.
Novavax has agreed to grant the Japanese licensing rights to NVX‑CoV2373, a vaccine candidate modified from the genetic sequence of the Covid-19 causing SARS‑CoV‑2 virus, to Takeda Pharmaceutical.
The high performance, inline oxygen sensors from METTLER TOLEDO stand the test of time under challenging operating conditions, whether in the biotechnology, pharmaceutical, brewing or food and beverage industry.
Johnson & Johnson (J&J) announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
Sanofi and GSK today announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.
The US International Development Finance Corporation (DFC) has agreed to provide a $765m loan to Eastman Kodak Company to help create a new pharmaceutical business unit.
The US government has placed an order worth $1.95bn to Pfizer and BioNTech to procure 100 million doses of their BNT162 vaccine candidate for Covid-19.
Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval.
Swiss pharmaceutical firm Novartis has announced that its Sandoz division will provide a portfolio of 15 not-for-profit generic and over-the-counter (OTC) medicines to developing countries to treat the patients with Covid-19 symptoms.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.